Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin versus cisplatin concurrent chemoradiotherapy for locally advanced low-risk nasopharyngeal carcinoma
ChiCTR1900021536Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lobaplatin and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 3-year progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
lobaplatincisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900021536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021536.